Israel Englander Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Millennium Management LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $556,738 - $753,160	-3,800 Reduced 62.3%	2,300 $343,000
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $5.92 Million - $7.69 Million	-39,100 Reduced 86.5%	6,100 $1.17 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $8.36 Million - $9.58 Million	45,200 New	45,200 $8.59 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $3.32 Million - $4.32 Million	17,900 New	17,900 $4.25 Million

639

107M

2.33M

2.15M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.